

Di Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6528308/publications.pdf>

Version: 2024-02-01

39
papers

1,058
citations

394421

19
h-index

434195

31
g-index

41
all docs

41
docs citations

41
times ranked

1621
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>In Situ</i> Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. <i>Nano Letters</i> , 2021, 21, 2224-2231.	9.1	116
2	Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. <i>Cell Death and Disease</i> , 2020, 11, 48.	6.3	103
3	CD93 promotes β 1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. <i>Journal of Clinical Investigation</i> , 2018, 128, 3280-3297.	8.2	100
4	Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19. <i>ACS Nano</i> , 2021, 15, 14347-14359.	14.6	73
5	Safe engineering of α CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. <i>EMBO Molecular Medicine</i> , 2016, 8, 702-711.	6.9	56
6	Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. <i>Science Signaling</i> , 2015, 8, ra125.	3.6	52
7	Double-Targeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability. <i>PLoS ONE</i> , 2010, 5, e8916.	2.5	43
8	Chondroitin Sulfate-Coated DNA Nanoplexes Enhance Transfection Efficiency by Controlling Plasmid Release from Endosomes: A New Insight into Modulating Nonviral Gene Transfection. <i>Advanced Functional Materials</i> , 2015, 25, 3907-3915.	14.9	43
9	Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Targeted Oncolytic Semliki Forest Virus. <i>Clinical Cancer Research</i> , 2017, 23, 1519-1530.	7.0	43
10	Multiple nuclear-replicating viruses require the stress-induced protein ZC3H11A for efficient growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3808-E3816.	7.1	35
11	Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors. <i>Journal of Virology</i> , 2011, 85, 13114-13123.	3.4	34
12	Vector-Encoded Helicobacter pylori Neutrophil-Activating Protein Promotes Maturation of Dendritic Cells with Th1 Polarization and Improved Migration. <i>Journal of Immunology</i> , 2014, 193, 2287-2296.	0.8	32
13	Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and <i>In Vivo</i> Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1705-1716.	4.1	32
14	An Infection-enhanced Oncolytic Adenovirus Secreting H. pylori Neutrophil-activating Protein with Therapeutic Effects on Neuroendocrine Tumors. <i>Molecular Therapy</i> , 2013, 21, 2008-2018.	8.2	29
15	Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. <i>Gene Therapy</i> , 2011, 18, 1052-1062.	4.5	27
16	Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14001.	4.1	27
17	Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures. <i>PLoS ONE</i> , 2013, 8, e54952.	2.5	25
18	CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumor responses in solid cancers. <i>Nature Biomedical Engineering</i> , 2022, 6, 830-841.	22.5	25

#	ARTICLE	IF	CITATIONS
19	Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer. <i>Neuroendocrinology</i> , 2017, 105, 54-66.	2.5	24
20	Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. <i>Oncolmmunology</i> , 2018, 7, e1395126.	4.6	24
21	Antischistosomal Properties of Hederacolchiside A1 Isolated from <i>Pulsatilla chinensis</i> . <i>Molecules</i> , 2018, 23, 1431.	3.8	20
22	Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. <i>Oncolmmunology</i> , 2018, 7, e1397250.	4.6	19
23	Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. <i>Immunotherapy</i> , 2016, 8, 1355-1361.	2.0	15
24	IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 37-46.	4.4	14
25	Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 977-991.	6.1	13
26	Tat-PTD-Modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy. <i>Human Gene Therapy</i> , 2013, 24, 766-775.	2.7	8
27	Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 356-366.	4.4	7
28	Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity. <i>Molecular Therapy - Oncolytics</i> , 2017, 7, 67-75.	4.4	6
29	Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response. <i>Oncolmmunology</i> , 2022, 11, .	4.6	5
30	A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells. <i>Journal of Immunotherapy</i> , 2014, 37, 155-162.	2.4	3
31	A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus Products. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.5	2
32	Abstract A041: Hypoxia-responsive CAR T-cells. , 2019, , .		1
33	A qPCR-Based Method for Quantification of Replication Competent Adenovirus (RCA) in Conditionally Replicating Oncolytic Adenoviruses. <i>Methods in Molecular Biology</i> , 2022, , 249-258.	0.9	1
34	HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID mice. <i>Virology</i> , 2016, 489, 44-50.	2.4	0
35	Abstract A171: Long-term episomal gene transfer for safe engineering of T cells for adoptive cell therapy of cancer. , 2016, , .		0
36	Abstract A172: Allogeneic dendritic cells (AlloDCs) transduced with an infection-enhanced adenovirus as adjuvant for cancer immunotherapy. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 2311: Adenovirus-transduced allogeneic dendritic cells for cancer immunotherapy. , 2016, , .		0
38	Abstract B110: Proinflammatory allogeneic dendritic cells promote activation of bystander immune cells and indirectly license antigen-specific T-cells. , 2019, , .		0
39	Abstract B175: Semliki Forest virus-mediated oncolytic immunotherapy in mouse GL261 glioblastoma model. , 2019, , .		0